Latest Market Entry News

Aumake Limited reports a robust 50% revenue increase to $39 million for FY25, driven by improving China-Australia trade relations. The company unveils a strategic pivot and corporate restructuring to sharpen its focus on profitable growth and brand incubation.

RLF AgTech Ltd has closed FY2025 with a remarkable 74% increase in customer receipts and positive operating cash flow, underpinned by a comprehensive restructuring and renewed market momentum across Australia, China, and Asia.

SRJ Technologies has taken a strategic leap by acquiring a UAE entity registered with a regional National Oil Company, positioning itself for direct contracting in the Middle East energy sector. This move is supported by a recent capital raise and ongoing restructuring to sharpen its regional focus.

BetMakers Technology Group capped FY25 with its strongest quarterly results ever, showcasing record profitability, positive cash flow, and a debt-free balance sheet. The company’s strategic investments and recent capital raise set the stage for accelerated growth in FY26, including a key acquisition in Nevada.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

Elsight Limited reports unprecedented revenue growth in Q2 and H1 2025, driven by major defence contracts and expanding market demand. The company is on track to achieve profitability in the second half of the year.

AnteoTech has signed a binding Term Sheet with US-based Black Diamond Structures to jointly develop and commercialise an advanced battery additive combining their proprietary technologies, targeting improved lithium-ion battery anodes with higher silicon content.

PainChek has completed its final FDA submission for the PainChek Adult App, targeting the US long-term care market with a potential $100 million annual opportunity. A regulatory decision is expected within 75 days, setting the stage for rapid commercialisation.

Mesoblast has reported a strong commercial debut for Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease, generating US$13.2 million in gross revenue in its initial quarter. The company is advancing regulatory and clinical milestones while expanding insurance coverage across the US.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.

Pure Resources advances its Reedy Creek project by exploring graphite potential and forging US partnerships to tap into thermal management and rare earth element technologies.

INOVIQ Limited reports strong clinical validation for its EXO-OC ovarian cancer screening test and promising preclinical results for CAR-exosome therapeutics targeting aggressive cancers.